(+)-schisandrin B multiple interactions EXP 6480464 schizandrin B inhibits the reaction [Carbon Tetrachloride results in decreased expression of SLC46A3 mRNA] CTD PMID:31150632 (-)-epigallocatechin 3-gallate multiple interactions ISO SLC46A3 (Homo sapiens) 6480464 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC46A3 mRNA CTD PMID:22079256 1,1-dichloroethene decreases expression ISO Slc46a3 (Mus musculus) 6480464 vinylidene chloride results in decreased expression of SLC46A3 mRNA CTD PMID:26682919 1,2-dimethylhydrazine decreases expression ISO Slc46a3 (Mus musculus) 6480464 1 and 2-Dimethylhydrazine results in decreased expression of SLC46A3 mRNA CTD PMID:22206623 17beta-estradiol multiple interactions ISO SLC46A3 (Homo sapiens) 6480464 [Estradiol co-treated with TGFB1 protein] results in increased expression of SLC46A3 mRNA CTD PMID:30165855 17beta-estradiol increases expression EXP 6480464 Estradiol results in increased expression of SLC46A3 mRNA CTD PMID:32145629 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO Slc46a3 (Mus musculus) 6480464 [Tetrachlorodibenzodioxin binds to AHR protein] which results in increased expression of SLC46A3 mRNA and [TIPARP gene mutant form results in increased susceptibility to Tetrachlorodibenzodioxin] which results in increased expression of SLC46A3 mRNA CTD PMID:16214954 and PMID:25975270 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO Slc46a3 (Mus musculus) 6480464 Tetrachlorodibenzodioxin results in increased expression of SLC46A3 mRNA CTD PMID:19770486 more ... 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO Slc46a3 (Mus musculus) 6480464 Tetrachlorodibenzodioxin affects the expression of SLC46A3 mRNA CTD PMID:20702594 and PMID:26377647 2,3,7,8-Tetrachlorodibenzofuran affects expression ISO Slc46a3 (Mus musculus) 6480464 2 more ... CTD PMID:20702594 3-isobutyl-1-methyl-7H-xanthine multiple interactions ISO SLC46A3 (Homo sapiens) 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of SLC46A3 mRNA CTD PMID:28628672 4,4'-sulfonyldiphenol decreases expression ISO Slc46a3 (Mus musculus) 6480464 bisphenol S results in decreased expression of SLC46A3 mRNA CTD PMID:33297965 7,12-dimethyltetraphene increases expression ISO Slc46a3 (Mus musculus) 6480464 9 more ... CTD PMID:32553695 acetamide decreases expression EXP 6480464 acetamide results in decreased expression of SLC46A3 mRNA CTD PMID:31881176 acrylamide affects expression EXP 6480464 Acrylamide affects the expression of SLC46A3 mRNA CTD PMID:28959563 aflatoxin B1 decreases expression ISO SLC46A3 (Homo sapiens) 6480464 Aflatoxin B1 results in decreased expression of SLC46A3 mRNA CTD PMID:27153756 aristolochic acid A increases expression ISO SLC46A3 (Homo sapiens) 6480464 aristolochic acid I results in increased expression of SLC46A3 mRNA CTD PMID:33212167 atrazine affects methylation EXP 6480464 Atrazine affects the methylation of SLC46A3 gene CTD PMID:28931070 benzo[a]pyrene increases expression ISO Slc46a3 (Mus musculus) 6480464 Benzo(a)pyrene metabolite results in increased expression of SLC46A3 mRNA and Benzo(a)pyrene results in increased expression of SLC46A3 mRNA CTD PMID:19770486 more ... benzo[a]pyrene decreases expression ISO SLC46A3 (Homo sapiens) 6480464 Benzo(a)pyrene results in decreased expression of SLC46A3 mRNA CTD PMID:32234424 benzo[a]pyrene affects methylation ISO SLC46A3 (Homo sapiens) 6480464 Benzo(a)pyrene affects the methylation of SLC46A3 promoter CTD PMID:27901495 benzo[a]pyrene multiple interactions ISO Slc46a3 (Mus musculus) 6480464 [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SLC46A3 mRNA and [Benzo(a)pyrene results in increased activity of AHR protein] which results in increased expression of SLC46A3 mRNA CTD PMID:27858113 and PMID:32553695 benzo[b]fluoranthene multiple interactions ISO Slc46a3 (Mus musculus) 6480464 [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SLC46A3 mRNA CTD PMID:27858113 Benzo[k]fluoranthene increases expression ISO Slc46a3 (Mus musculus) 6480464 benzo(k)fluoranthene results in increased expression of SLC46A3 mRNA CTD PMID:26377693 bis(2-chloroethyl) sulfide increases expression ISO SLC46A3 (Homo sapiens) 6480464 Mustard Gas results in increased expression of SLC46A3 mRNA CTD PMID:25102026 bis(2-ethylhexyl) phthalate increases expression ISO SLC46A3 (Homo sapiens) 6480464 Diethylhexyl Phthalate results in increased expression of SLC46A3 mRNA CTD PMID:31163220 bisphenol A decreases expression EXP 6480464 bisphenol A results in decreased expression of SLC46A3 mRNA CTD PMID:30816183 and PMID:32528016 bisphenol A decreases expression ISO Slc46a3 (Mus musculus) 6480464 bisphenol A results in decreased expression of SLC46A3 mRNA CTD PMID:32156529 bisphenol A decreases methylation ISO SLC46A3 (Homo sapiens) 6480464 bisphenol A results in decreased methylation of SLC46A3 gene CTD PMID:31601247 bisphenol A increases expression ISO Slc46a3 (Mus musculus) 6480464 bisphenol A results in increased expression of SLC46A3 mRNA CTD PMID:34585602 bisphenol A affects expression EXP 6480464 bisphenol A affects the expression of SLC46A3 mRNA CTD PMID:32145629 bisphenol F multiple interactions ISO SLC46A3 (Homo sapiens) 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of SLC46A3 mRNA CTD PMID:28628672 cadmium atom multiple interactions ISO Slc46a3 (Mus musculus) 6480464 [Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of SLC46A3 mRNA CTD PMID:37325564 cadmium dichloride multiple interactions ISO Slc46a3 (Mus musculus) 6480464 [Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of SLC46A3 mRNA CTD PMID:37325564 carbon nanotube decreases expression ISO Slc46a3 (Mus musculus) 6480464 Nanotubes more ... CTD PMID:25554681 and PMID:25620056 cefaloridine increases expression EXP 6480464 Cephaloridine results in increased expression of SLC46A3 mRNA CTD PMID:18500788 chlorpyrifos increases expression ISO Slc46a3 (Mus musculus) 6480464 Chlorpyrifos results in increased expression of SLC46A3 mRNA CTD PMID:32715474 chromium(6+) decreases expression ISO SLC46A3 (Homo sapiens) 6480464 chromium hexavalent ion results in decreased expression of SLC46A3 mRNA CTD PMID:30690063 chrysene multiple interactions ISO Slc46a3 (Mus musculus) 6480464 [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SLC46A3 mRNA CTD PMID:27858113 cisplatin multiple interactions ISO SLC46A3 (Homo sapiens) 6480464 [Cisplatin co-treated with jinfukang] results in increased expression of SLC46A3 mRNA CTD PMID:27392435 clofibrate decreases expression ISO Slc46a3 (Mus musculus) 6480464 Clofibrate results in decreased expression of SLC46A3 mRNA CTD PMID:23811191 cyclosporin A decreases expression ISO SLC46A3 (Homo sapiens) 6480464 Cyclosporine results in decreased expression of SLC46A3 mRNA CTD PMID:20106945 dexamethasone multiple interactions ISO SLC46A3 (Homo sapiens) 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of SLC46A3 mRNA CTD PMID:28628672 dibenzofurans increases expression ISO Slc46a3 (Mus musculus) 6480464 Dibenzofurans results in increased expression of SLC46A3 mRNA CTD PMID:34254344 dichloroacetic acid decreases expression ISO Slc46a3 (Mus musculus) 6480464 Dichloroacetic Acid results in decreased expression of SLC46A3 mRNA CTD PMID:28962523 diclofenac decreases expression ISO Slc46a3 (Mus musculus) 6480464 Diclofenac results in decreased expression of SLC46A3 mRNA CTD PMID:35537566 dioxygen increases expression ISO SLC46A3 (Homo sapiens) 6480464 Oxygen deficiency results in increased expression of SLC46A3 mRNA CTD PMID:26516004 dorsomorphin multiple interactions ISO SLC46A3 (Homo sapiens) 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 doxorubicin decreases expression ISO SLC46A3 (Homo sapiens) 6480464 Doxorubicin results in decreased expression of SLC46A3 mRNA CTD PMID:29803840 entinostat increases expression ISO SLC46A3 (Homo sapiens) 6480464 entinostat results in increased expression of SLC46A3 mRNA CTD PMID:27188386 epoxiconazole affects expression ISO Slc46a3 (Mus musculus) 6480464 epoxiconazole affects the expression of SLC46A3 mRNA CTD PMID:35436446 ethylparaben increases expression ISO SLC46A3 (Homo sapiens) 6480464 ethyl-p-hydroxybenzoate results in increased expression of SLC46A3 mRNA CTD PMID:37690743 ferric oxide decreases expression ISO Slc46a3 (Mus musculus) 6480464 ferric oxide analog results in decreased expression of SLC46A3 mRNA CTD PMID:25086211 gentamycin decreases expression EXP 6480464 Gentamicins results in decreased expression of SLC46A3 mRNA CTD PMID:33387578 glafenine decreases expression EXP 6480464 Glafenine results in decreased expression of SLC46A3 mRNA CTD PMID:24136188 indometacin multiple interactions ISO SLC46A3 (Homo sapiens) 6480464 [INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of SLC46A3 mRNA CTD PMID:28628672 isotretinoin decreases expression ISO SLC46A3 (Homo sapiens) 6480464 Isotretinoin results in decreased expression of SLC46A3 mRNA CTD PMID:20436886 lipopolysaccharide multiple interactions ISO SLC46A3 (Homo sapiens) 6480464 [S-(1 and 2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of SLC46A3 mRNA CTD PMID:35811015 lipopolysaccharide decreases expression ISO SLC46A3 (Homo sapiens) 6480464 Lipopolysaccharides results in decreased expression of SLC46A3 mRNA CTD PMID:35811015 metformin decreases expression EXP 6480464 Metformin results in decreased expression of SLC46A3 mRNA CTD PMID:31324951 Muraglitazar decreases expression EXP 6480464 muraglitazar results in decreased expression of SLC46A3 mRNA CTD PMID:21515302 nickel sulfate increases expression ISO SLC46A3 (Homo sapiens) 6480464 nickel sulfate results in increased expression of SLC46A3 mRNA CTD PMID:22714537 oxaliplatin decreases expression EXP 6480464 oxaliplatin results in decreased expression of SLC46A3 mRNA CTD PMID:25729387 oxaliplatin multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in decreased expression of SLC46A3 mRNA CTD PMID:25729387 paracetamol affects expression ISO Slc46a3 (Mus musculus) 6480464 Acetaminophen affects the expression of SLC46A3 mRNA CTD PMID:17562736 paracetamol increases expression EXP 6480464 Acetaminophen results in increased expression of SLC46A3 mRNA CTD PMID:33387578 paracetamol decreases expression ISO SLC46A3 (Homo sapiens) 6480464 Acetaminophen results in decreased expression of SLC46A3 mRNA CTD PMID:29067470 perfluorohexanesulfonic acid increases expression ISO Slc46a3 (Mus musculus) 6480464 perfluorohexanesulfonic acid results in increased expression of SLC46A3 mRNA CTD PMID:37995155 perfluorononanoic acid decreases expression ISO SLC46A3 (Homo sapiens) 6480464 perfluoro-n-nonanoic acid results in decreased expression of SLC46A3 mRNA CTD PMID:32588087 phenylmercury acetate increases expression ISO SLC46A3 (Homo sapiens) 6480464 Phenylmercuric Acetate results in increased expression of SLC46A3 mRNA CTD PMID:26272509 phenylmercury acetate multiple interactions ISO SLC46A3 (Homo sapiens) 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC46A3 mRNA CTD PMID:27188386 pirinixic acid multiple interactions ISO Slc46a3 (Mus musculus) 6480464 [pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of SLC46A3 mRNA CTD PMID:19710929 pirinixic acid decreases expression ISO Slc46a3 (Mus musculus) 6480464 pirinixic acid results in decreased expression of SLC46A3 mRNA CTD PMID:23811191 potassium chromate multiple interactions ISO SLC46A3 (Homo sapiens) 6480464 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of SLC46A3 mRNA CTD PMID:22079256 potassium chromate decreases expression ISO SLC46A3 (Homo sapiens) 6480464 potassium chromate(VI) results in decreased expression of SLC46A3 mRNA CTD PMID:22079256 and PMID:22714537 pregnenolone 16alpha-carbonitrile decreases expression ISO Slc46a3 (Mus musculus) 6480464 Pregnenolone Carbonitrile results in decreased expression of SLC46A3 mRNA CTD PMID:28903501 progesterone increases expression ISO SLC46A3 (Homo sapiens) 6480464 Progesterone results in increased expression of SLC46A3 mRNA CTD PMID:20864642 resveratrol multiple interactions ISO SLC46A3 (Homo sapiens) 6480464 [Plant Extracts co-treated with Resveratrol] results in increased expression of SLC46A3 mRNA CTD PMID:23557933 rifampicin increases expression ISO SLC46A3 (Homo sapiens) 6480464 Rifampin results in increased expression of SLC46A3 mRNA CTD PMID:27199754 rotenone increases expression EXP 6480464 Rotenone results in increased expression of SLC46A3 mRNA CTD PMID:28374803 S-(1,2-dichlorovinyl)-L-cysteine multiple interactions ISO SLC46A3 (Homo sapiens) 6480464 [S-(1 and 2-dichlorovinyl)cysteine affects the susceptibility to Lipopolysaccharides] which results in increased expression of SLC46A3 mRNA CTD PMID:35811015 SB 431542 multiple interactions ISO SLC46A3 (Homo sapiens) 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 silicon dioxide decreases expression ISO SLC46A3 (Homo sapiens) 6480464 Silicon Dioxide analog results in decreased expression of SLC46A3 mRNA CTD PMID:25895662 silicon dioxide increases expression ISO SLC46A3 (Homo sapiens) 6480464 Silicon Dioxide analog results in increased expression of SLC46A3 mRNA and Silicon Dioxide results in increased expression of SLC46A3 mRNA CTD PMID:23806026 and PMID:25351596 sodium arsenite decreases expression ISO Slc46a3 (Mus musculus) 6480464 sodium arsenite results in decreased expression of SLC46A3 mRNA CTD PMID:37668303 Soman decreases expression EXP 6480464 Soman results in decreased expression of SLC46A3 mRNA CTD PMID:19281266 sunitinib decreases expression ISO SLC46A3 (Homo sapiens) 6480464 Sunitinib results in decreased expression of SLC46A3 mRNA CTD PMID:31533062 Tesaglitazar decreases expression EXP 6480464 tesaglitazar results in decreased expression of SLC46A3 mRNA CTD PMID:21515302 tetrachloroethene decreases expression ISO Slc46a3 (Mus musculus) 6480464 Tetrachloroethylene results in decreased expression of SLC46A3 mRNA CTD PMID:28973375 tetrachloromethane decreases expression ISO Slc46a3 (Mus musculus) 6480464 Carbon Tetrachloride results in decreased expression of SLC46A3 mRNA CTD PMID:27339419 and PMID:31919559 tetrachloromethane multiple interactions EXP 6480464 schizandrin B inhibits the reaction [Carbon Tetrachloride results in decreased expression of SLC46A3 mRNA] CTD PMID:31150632 tetrachloromethane decreases expression EXP 6480464 Carbon Tetrachloride results in decreased expression of SLC46A3 mRNA CTD PMID:31150632 tetraphene multiple interactions ISO Slc46a3 (Mus musculus) 6480464 [Benzo(a)pyrene co-treated with benz(a)anthracene co-treated with benzo(b)fluoranthene co-treated with chrysene] results in increased expression of SLC46A3 mRNA CTD PMID:27858113 thioacetamide decreases expression EXP 6480464 Thioacetamide results in decreased expression of SLC46A3 mRNA CTD PMID:23411599 and PMID:34492290 topotecan decreases expression EXP 6480464 Topotecan results in decreased expression of SLC46A3 mRNA CTD PMID:25729387 topotecan multiple interactions EXP 6480464 [oxaliplatin co-treated with Topotecan] results in decreased expression of SLC46A3 mRNA CTD PMID:25729387 tremolite asbestos decreases expression ISO Slc46a3 (Mus musculus) 6480464 tremolite results in decreased expression of SLC46A3 mRNA CTD PMID:29279043 trichloroethene increases expression EXP 6480464 Trichloroethylene results in increased expression of SLC46A3 mRNA CTD PMID:33387578 trichostatin A increases expression ISO SLC46A3 (Homo sapiens) 6480464 trichostatin A results in increased expression of SLC46A3 mRNA CTD PMID:24935251 trovafloxacin decreases expression ISO Slc46a3 (Mus musculus) 6480464 trovafloxacin results in decreased expression of SLC46A3 mRNA CTD PMID:35537566 valproic acid increases expression ISO Slc46a3 (Mus musculus) 6480464 Valproic Acid results in increased expression of SLC46A3 mRNA CTD PMID:21427059 valproic acid increases expression ISO SLC46A3 (Homo sapiens) 6480464 Valproic Acid results in increased expression of SLC46A3 mRNA CTD PMID:19101580 more ... valproic acid multiple interactions ISO SLC46A3 (Homo sapiens) 6480464 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC46A3 mRNA CTD PMID:27188386 valproic acid affects expression ISO SLC46A3 (Homo sapiens) 6480464 Valproic Acid affects the expression of SLC46A3 mRNA CTD PMID:25979313 vinclozolin decreases expression EXP 6480464 vinclozolin results in decreased expression of SLC46A3 mRNA CTD PMID:23034163 zoledronic acid increases expression ISO SLC46A3 (Homo sapiens) 6480464 zoledronic acid results in increased expression of SLC46A3 mRNA CTD PMID:24714768